$BCLI

BrainStorm Cell Therapeutics (OTCQB: BCLI) reported Q2 2026 results for the quarter ended June 30, 2026. It said it is preparing to start the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, planning about 200 patients. Cash was about $0.2M vs $1.03M a year earlier, with Q2 net loss about $3.9M. The company appointed Peter J. Pitts as Executive Chairman and raised about $400k in private placements.

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2623188d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, Aug 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adu

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.2 3 tm2621592d1_ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 BRAINSTORM CELL THERAPEUTIC INC. 2014 STOCK INCENTIVE PLAN STOCK OPTION GRANT NOTICE Brainstorm Cell Therapeutics Inc., a Delaware corporation, (the “ Company ”), pursuant to its 2014 Stock Incentive Plan, as may be amend

PHILADELPHIA, Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Grabar Law Office is investigating claims on behalf of shareholders of Alto Neuroscience, Inc. ANRO. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

BrainStorm Cell Therapeutics Inc. BCLI shares crashed 42.74% to $0.67 in after-hours trading on Friday after the company announced its voluntary delisting from the Nasdaq Capital Market.